At MediMix, we are dedicated to keeping Belgian healthcare professionals at the forefront of medicine. Our team brings you high-value insights from leading congresses worldwide, across key disease areas including hematology. In collaboration with Belgian and international experts, we transform the latest data into practical knowledge.
At ASH 2025, Prof Dr Valeria Santini presented the results of an ad hoc analysis of the COMMANDS trial focusing on clinically meaningful predictors of response to first-line therapy in
In this video, Dr Marie Vercruyssen, hematologist at the Institut Jules Bordet in Brussels shares the key takeaways from 4 presentations related to multiple myeloma (MM) presented at ASH 2025.
In this video, Prof Hanny Al-Samkari, hematologist and clinical investigator, summarized findings from a poster presented at ASH 2025 examining overall survival (OS) in patients with metastatic colorectal cancer (mCRC)
In this video, Prof Vania Hungria, hematologist, summarizes the results from a subgroup analysis of the phase III DREAMM-7 and DREAMM-8 studies, evaluating belantamab mafodotin–based combinations in patients with relapsed
At ASH 2025, Prof Heinz Ludwig, haematologist presented a poster describing the results of a randomized phase II AGMT-MM04 study. This trial evaluated the efficacy and safety of isatuximab plus
At the 2025 American Society of Hematology (ASH) Annual Meeting, Prof Elias Jabbour, hematologist, presented updated results from a phase 1b study evaluating subcutaneous blinatumomab in patients with relapsed or
At ASH 2025, Prof Dr Joshua Zeidner presented a poster reporting results from a real-world analysis of frontline treatment with ivosidenib plus azacitidine (IVO-AZA) in older, unfit patients with IDH1-mutated
At ASH 2025, Prof Dr Phoebe Joy Ho presented a late-breaking abstract at ASH 2025 describing a first-in-human clinical trial of in vivo CAR T-cell therapy for multiple myeloma.
